clipped from blogs.wsj.comThe discussion of that big Vytorin study at this weekend’s big cardiology meeting was harsher than expected. Industry observers had predicted that an open conversation by the experts could temper the negative image of the drug that emerged earlier this year after the study results were made public, but just the opposite… This is a summary of the content. Read the article in its entirety at the Alzheimer’s Reading Room.

More: continued here